ITM Isotope Technologies Munich News and Activities

Acquisition, funding and merger involving ITM Isotope Technologies Munich.

• ITM Isotope Technologies Munich has just announced a $262 Million fundraising (posted on May 28 2025).

View the org chart displaying its 32 main executives

Most searched biographies at ITM Isotope Technologies Munich

• Andrew Cavey, Chief Executive Officer
• Udo Vetter, Chairman of the Board
• Tadd Wessel, Director

Popular executive movements at ITM Isotope Technologies Munich

• Steve Cifelli has joined the company as Senior Director of Business Strategy and Analytics  (posted on March 31 2026).
• Annette Breunig has joined the company as Chief People Officer  (posted on October 14 2025).

Create your alert
to follow the executive moves at ITM Isotope Technologies Munich.

ITM Isotope Technologies Munich has 1,235 competitors including Thermo Fisher Scientific (United States (USA)), Medtronic (Ireland) and Philips (Netherlands).

Popular M&A news in Medical Equipment

• Bridgepoint has announced the acquisition of Obagi Medical Products  (posted on June 4 2026).
• Niowave has just announced a $70 Million fundraising (posted on June 2 2026).
• The new name of Edap Tms is FocalTherics. (posted on June 1 2026).

Popular contacts in Medical Equipment

• Kweli Thompson - Executive Vice President and President, Neuroscience Portfolio at Medtronic
• Jacob Thaysen - Chief Executive Officer and Director at Illumina
• Ivan Tornos - Chairman, President and Chief Executive Officer at Zimmer Biomet

Learn more about the Medical Equipment industry

Press releases by ITM Isotope Technologies Munich

• ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026
• ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
• ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium
• ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
• ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
• ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
• ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference
• ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma
• ITM to Participate in Upcoming Investor Conferences
• ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
• View more press releases Close

Social media about ITM Isotope Technologies Munich

• ITM Isotope Technologies Munich on Wikipedia, Google News & Yahoo Finance
• ITM Isotope Technologies Munich on LinkedIn, X (Twitter) & YouTube